Bixiye
QP7-20 Pharmacy Benefit Exclusion for Vyondys 53 (golodirsen)
Taariikhda uu dhaqangalayo Barnaamijka: Jan 08, 2020
Natiijooyinka Raadinta
Soo bandhiga 2541 - 2550 ee natiijooyinka 3698
Bixiye
QP14-20 New Service Type Options for Inpatient Admission Notifications on Availity Portal
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP13-20 Blue Cross Blue Shield National Coordination of Care SM Overview
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP11-20 Pharmacy Benefit Exclusion for Budesonide-Formoterol Fumarate Dihydrate Aerosol
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP10-20 Pharmacy Benefit Exclusion for Xenleta TM, Asparlas TM, Ogivri TM and Tranexamic Acid/Sodium Chloride
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP9-20 Pharmacy Benefit Exclusion Healthcare Administered Drugs
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP15-20 Commercial Medical Drug Exclusion List Expanded to Include Avsola
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
P4-20 Lab Management Clinical Guideline Updates for Fully Insured Commercial and Medicare Advantage Subscribers – eviCore Healthcare Specialty Utilization Management (UM) Program
Taariikhda uu dhaqangalayo Barnaamijka: Jan 02, 2020
Bixiye
QP107-19 Medical Drug Update for Rituximab Biosimilars (Truxima, Ruxience) – Commercial Products
Taariikhda uu dhaqangalayo Barnaamijka: Des 11, 2019
Bixiye
QP105-19 Understanding Vision Benefits within Eligibility & Benefits Inquiry Response
Taariikhda uu dhaqangalayo Barnaamijka: Des 11, 2019